Latest article
Lilly’s tirzepatide beats Ozempic in head-to-head kind 2 diabetes trial
Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Take a look at fitness center, health middle earlier than becoming a member of
If this is your year of wanting to control your weight and fitness, you'll have more power.Most likely, you will need to commit to...
Addressing the Impression of Structural Racism on Disparities in Youngsters with Kind 1 Diabetes
Newswise - PHILADELPHIA, PA (Jan 22, 2021) - Advances in diabetes technology have improved the quality of life and blood sugar control in children...